Loading
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Previous close
$8.87
+$0.12 · +1.37%
After-hours
$8.88
+$0.01 · +0.11%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Day range
Current $8.87
52-week range
Current $8.87
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
49
Mixed
Risk
47
Elevated Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Day range
Current $8.87
52-week range
Current $8.87
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 75K USD | 73K USD |
| Cost of goods sold | 481K USD | 396K USD | 343K USD | — | 9K USD |
| Gross profit | −481K USD | −396K USD | −343K USD | 75K USD | 64K USD |
| Research and development | 23.39M USD | 18.33M USD | 15.61M USD | 12.77M USD | 11.27M USD |
| Selling, general, and administrative | 27.8M USD | 23.43M USD | 6.99M USD | 6.38M USD | 6.65M USD |
| Operating expenses | 50.71M USD | 41.37M USD | 22.49M USD | 19.16M USD | 17.92M USD |
| Interest income | 5.57M USD | — | 904K USD | — | — |
| Interest expense | — | −3.29M USD | — | 33K USD | 32K USD |
| Depreciation and amortization | 481K USD | 396K USD | 343K USD | 381K USD | 392K USD |
| Operating income | −51.19M USD | −41.77M USD | −22.49M USD | −19.08M USD | −17.85M USD |
| Net income | −45.55M USD | −37.92M USD | −21.75M USD | −19.56M USD | −18.21M USD |
Company facts updated Oct 10, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Simplify Health Care ETFPINK9.69M3.04%312.13M USD0.51%$38.527+2.57%
Vanguard Morningstar Total Stock Market ETFVTI7.9M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM4.77M0.01%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF3.53M0.00%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Value ETFIWN1.64M0.01%13.85B USD0.24%$210.87-0.04%
Vanguard Russell 2000 ETFVTWO1.49M0.01%18B USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC584.61K0.04%1.32B USD0.60%$183+0.11%
Vanguard Russell 2000 Value ETFVTWV226.36K0.02%1.4B USD0.06%$185.81-0.13%Simplify Health Care ETFPINKVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
